UBS Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-1,200
| Closed | -$1K | – | 8548 |
|
|
2019
Q1 | $1K | Hold |
1,200
| – | – | ﹤0.01% | 7658 |
|
|
2018
Q4 | $1K | Hold |
1,200
| – | – | ﹤0.01% | 7977 |
|
|
2018
Q3 | $3K | Sell |
1,200
-1,164
| -49% | -$2.79K | ﹤0.01% | 7710 |
|
|
2018
Q2 | $6K | Buy |
2,364
+1,164
| +97% | +$3.39K | ﹤0.01% | 7447 |
|
|
2018
Q1 | $4K | Sell |
1,200
-5,237
| -81% | -$14.4K | ﹤0.01% | 7391 |
|
|
2017
Q4 | $27K | Buy |
6,437
+1,026
| +19% | +$4.46K | ﹤0.01% | 6347 |
|
|
2017
Q3 | $25K | Buy |
5,411
+1,745
| +48% | +$7.07K | ﹤0.01% | 6313 |
|
|
2017
Q2 | $12K | Sell |
3,666
-321
| -8% | -$1.33K | ﹤0.01% | 6691 |
|
|
2017
Q1 | $37K | Sell |
3,987
-4,326
| -52% | -$38K | ﹤0.01% | 5738 |
|
|
2016
Q4 | $65K | Sell |
8,313
-457
| -5% | -$4.2K | ﹤0.01% | 5624 |
|
|
2016
Q3 | $100K | Buy |
8,770
+4,486
| +105% | +$52.2K | ﹤0.01% | 4993 |
|
|
2016
Q2 | $53K | Sell |
4,284
-2,059
| -32% | -$25K | ﹤0.01% | 5485 |
|
|
2016
Q1 | $64K | Sell |
6,343
-6,038
| -49% | -$70.9K | ﹤0.01% | 5309 |
|
|
2015
Q4 | $279K | Buy |
12,381
+8,272
| +201% | +$169K | ﹤0.01% | 4416 |
|
|
2015
Q3 | $68K | Sell |
4,109
-1,308
| -24% | -$26.2K | ﹤0.01% | 5549 |
|
|
2015
Q2 | $122K | Buy |
5,417
+1,008
| +23% | +$24.9K | ﹤0.01% | 5248 |
|
|
2015
Q1 | $114K | Buy |
4,409
+986
| +29% | +$25K | ﹤0.01% | 5311 |
|
|
2014
Q4 | $75K | Buy |
+3,423
| New | +$70.1K | ﹤0.01% | 6011 |
|
UBS Group's OMED Position: Q2 2019 in Review
UBS Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 1,200 shares — an estimated $1K sold.
UBS Group first reported a position in OMED in Q4 2014 and held it in 18 quarters. The position peaked at $279K in Q4 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- UBS Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- UBS Group sold 1,200 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $1K.
- UBS Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 18 quarters.
- UBS Group's OncoMed Pharmaceuticals, Inc. position peaked at $279K in Q4 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.